CA Patent

CA3031705A1 — Treatment of prostate cancer with niraparib

Assigned to Janssen Pharmaceutica NV · Expires 2018-02-01 · 8y expired

What this patent protects

Disclosed are methods of treating prostate cancer by administering niraparib to a subject in need thereof.

USPTO Abstract

Disclosed are methods of treating prostate cancer by administering niraparib to a subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number: CA3031705A1
Jurisdiction: CA
Classification: —
Expires: 2018-02-01
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Pharmaceutica NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.